The market expects Incyte (INCY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is ...
Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after ...
Incyte Corporation offers strong growth potential and a low valuation, driven by expanding margins and a robust earnings outlook. INCY's revenue is anchored by Jakafi, but a diverse pipeline and ...
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte, with a price target of $101.00. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Kymera ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Wells Fargo’s recent downgrade of Incyte (INCY) to a more neutral rating, citing ...
Fintel reports that on February 5, 2026, HC Wainwright & Co. initiated coverage of Incyte (NasdaqGS:INCY) with a Buy recommendation. Analyst Price Forecast Suggests 1.68% Upside As of February 4, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results